Difference between revisions of "Oxymetazoline"

(Contraindications)
(References)
 
(3 intermediate revisions by 2 users not shown)
Line 36: Line 36:
  
 
==Pharmacology==
 
==Pharmacology==
*Half-life:  
+
*Half-life: not available
*Metabolism:  
+
*Metabolism: not available
*Excretion:  
+
*Excretion: not available
  
 
==Mechanism of Action==
 
==Mechanism of Action==
 +
*Stimulates α-adrenergic recepter in arterioles of nasal mucosa, produce vasoconstriction
  
 
==Comments==
 
==Comments==
Line 49: Line 50:
 
<references/>
 
<references/>
 
[[Category:Pharmacology]]
 
[[Category:Pharmacology]]
 +
[[Category:ENT]]

Latest revision as of 00:50, 23 September 2019

Administration

  • Type: Decongestant; Adrenergic Agonist Agent; Imidazoline derivative
  • Dosage Forms: Solution; Nasal spray
  • Routes of Administration: Intranasal
  • Common Trade Names: 12-Hour Nasal Relieve Spray, Afrin, Mucinex, Distran, Neo-synephrine

Adult Dosing

  • Instill 2-3 sprays for each nostrils twice daily for ≤3 days

Pediatric Dosing

  • Children ≥6 years: Instill 2-3 sprays for each nostrils twice daily for ≤3 days

Special Populations

Renal Dosing

  • Adult: Not needed
  • Pediatric: Not needed

Hepatic Dosing

  • Adult: Not needed
  • Pediatric: Not needed

Contraindications

  • Allergy to class/drug

Warnings/Precautions

  • Use with caution in patients with hypertension, heart failure or coronary artery disease
  • Use with caution in patients with diabetes mellitus
  • Use with caution in patients with hyperthyroidism
  • Use with caution in patients with benign prostatic hyperplasia

Adverse Reactions

Serious

  • Rebound nasal congestion may occur with extended use

Common

Pharmacology

  • Half-life: not available
  • Metabolism: not available
  • Excretion: not available

Mechanism of Action

  • Stimulates α-adrenergic recepter in arterioles of nasal mucosa, produce vasoconstriction

Comments

See Also

References